Skip to content
Medical Health Aged Care

Tribute to FIP President, the late Dominique Jordan

Pharmaceutical Society of Australia (PSA) < 1 mins read

20 August 2023

The Pharmaceutical Society of Australia (PSA) is today paying tribute to International Pharmaceutical Federation (FIP) President Mr Dominique Jordan, who sadly passed away overnight.

A Swiss community pharmacist, Dominique became a member of FIP 20 years ago. In his home country, his actions to advance pharmacy included roles as president and CEO, concurrently, of pharmaSuisse, the Swiss association of pharmacists.

Dominique was elected president of FIP in 2018. Before that, he served FIP and global pharmacy as chair of the Board of Pharmaceutical Practice (2014-2018). 

PSA National President Dr Fei Sim FPS paid tribute to Mr Jordan.

“Despite his ongoing battle with cancer, Dominique always captured the tenacity and positivity in life,” Dr Sim said.

“Dominique has worked tirelessly and given much of his life to professional pharmacy both in Australia and internationally and leaves a huge legacy to the profession. He will be greatly missed.

“On behalf of Australian pharmacists, PSA offers our deepest condolences to Mr Jordan’s friends, family, and colleagues.”

As per FIP Statutes (article 16.13), president-elect Paul Sinclair AM MPS will begin his term effective immediately.

 

Media contact:   Georgia Clarke   M: 0480 099 798      E: [email protected]

The Pharmaceutical Society of Australia is the only national peak body that represents all of Australia’s 36,000 pharmacists across all practice settings. We want every Australian to have access to the best healthcare, and this must include optimising access to pharmacists’ knowledge and medicines expertise at the forefront of our healthcare system.

Follow us on socials:      Facebook     Twitter      LinkedIn     Instagram

More from this category

  • Medical Health Aged Care
  • 07/12/2025
  • 01:41
Takeda Pharmaceutical Company Limited

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline NEWARK,…

  • Medical Health Aged Care
  • 06/12/2025
  • 02:11
Arthur D. Little

Arthur D. Little and Vega IT Unveil Joint Venture for Digital Innovation

NEW YORK–BUSINESS WIRE– Arthur D. Little (ADL) and Vega IT today announced the formation of Axceler8 Solutions, a 50/50 joint venture created to design,…

  • Contains:
  • Medical Health Aged Care, Women
  • 05/12/2025
  • 10:11
Breast Cancer Trials

Bec’s Christmas wish amid cancer treatment

This Christmas, Bec’s wish is for her daughters to never face a breast cancer diagnosis like she has. “The only thing tougher than telling…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.